NI201100212A - Inyección de diacetato de ipamorelin y soluciones de la infusión - Google Patents
Inyección de diacetato de ipamorelin y soluciones de la infusiónInfo
- Publication number
- NI201100212A NI201100212A NI201100212A NI201100212A NI201100212A NI 201100212 A NI201100212 A NI 201100212A NI 201100212 A NI201100212 A NI 201100212A NI 201100212 A NI201100212 A NI 201100212A NI 201100212 A NI201100212 A NI 201100212A
- Authority
- NI
- Nicaragua
- Prior art keywords
- ipamorelin
- injection
- infusion solutions
- diacetate
- acetic acid
- Prior art date
Links
- NEHWBYHLYZGBNO-BVEPWEIPSA-N (2s)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)C(C)(N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 NEHWBYHLYZGBNO-BVEPWEIPSA-N 0.000 title abstract 5
- 229950002987 ipamorelin Drugs 0.000 title abstract 5
- 108010027047 ipamorelin Proteins 0.000 title abstract 5
- 239000003978 infusion fluid Substances 0.000 title abstract 2
- 239000007924 injection Substances 0.000 title abstract 2
- 238000002347 injection Methods 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Peptides Or Proteins (AREA)
Abstract
Soluciones de la inyección y de infusión de ipamorelin que tienen la siguiente composición: a) ipamorelin solubilizado por aproximadamente dos equivalentes morales de ácido acético ( diacetato de ipamorelin), en una cantidad a partir de 0.001 al 20%, basada en el peso de la base libre de ipamorelin; b) un exceso molar de ácido, preferiblemente ácido acético, en cantidad suficiente para dar un PH de por lo menos 3 y menos de 7; C) opcionalmente a partir de 0.1 al 30% de una o más ayudas de la formulación; y d) agua q.s. al 100%; todos los porcentajes basados en el peso total de la solución.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18659509P | 2009-06-12 | 2009-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201100212A true NI201100212A (es) | 2012-04-11 |
Family
ID=42272260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201100212A NI201100212A (es) | 2009-06-12 | 2011-12-07 | Inyección de diacetato de ipamorelin y soluciones de la infusión |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20100317581A1 (es) |
| EP (1) | EP2440180B1 (es) |
| JP (1) | JP2012529510A (es) |
| KR (1) | KR20120030530A (es) |
| CN (1) | CN102481251A (es) |
| AU (1) | AU2010259102B2 (es) |
| BR (1) | BRPI1012931A2 (es) |
| CA (1) | CA2765233A1 (es) |
| CL (1) | CL2011003131A1 (es) |
| CO (1) | CO6470880A2 (es) |
| CR (1) | CR20110618A (es) |
| CU (1) | CU20110232A7 (es) |
| DO (1) | DOP2011000383A (es) |
| EA (1) | EA201270011A1 (es) |
| EC (1) | ECSP11011516A (es) |
| GT (1) | GT201100318A (es) |
| MX (1) | MX2011013113A (es) |
| NI (1) | NI201100212A (es) |
| NZ (1) | NZ596641A (es) |
| PE (1) | PE20121064A1 (es) |
| SG (1) | SG176717A1 (es) |
| TW (1) | TW201106961A (es) |
| UA (1) | UA104762C2 (es) |
| WO (1) | WO2010144265A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6193017B2 (ja) * | 2013-06-28 | 2017-09-06 | テルモ株式会社 | 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ |
| JP6562902B2 (ja) | 2014-03-28 | 2019-08-21 | テルモ株式会社 | 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU224345B1 (hu) | 1993-12-23 | 2005-08-29 | Novo Nordisk A/S. | Növekedési hormont felszabadító tulajdonságú peptidek, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk |
| WO2000074702A1 (en) * | 1999-06-04 | 2000-12-14 | Novo Nordisk A/S | Compositions for the treatment of the catabolic state of prolonged critical illness |
| EP1817049B1 (en) * | 2004-11-22 | 2012-08-01 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
| KR100700869B1 (ko) * | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물 |
| CA2790018C (en) * | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| JP2011507842A (ja) * | 2007-12-21 | 2011-03-10 | ヘルシン・セラピューティクス・ユーエス・インコーポレイテッド | 消化器系の運動をイパモレリンを用いて刺激する方法 |
| UA105657C2 (uk) * | 2009-02-27 | 2014-06-10 | Хелсінн Терапьютікс (Ю.Ес.), Інк. | Поліпшені способи лікування мігрені на основі анамореліну |
-
2010
- 2010-05-27 JP JP2012514986A patent/JP2012529510A/ja active Pending
- 2010-05-27 KR KR1020127000847A patent/KR20120030530A/ko not_active Application Discontinuation
- 2010-05-27 NZ NZ596641A patent/NZ596641A/en not_active IP Right Cessation
- 2010-05-27 SG SG2011090537A patent/SG176717A1/en unknown
- 2010-05-27 EP EP10720981.9A patent/EP2440180B1/en not_active Not-in-force
- 2010-05-27 PE PE2011002082A patent/PE20121064A1/es not_active Application Discontinuation
- 2010-05-27 CN CN2010800260526A patent/CN102481251A/zh active Pending
- 2010-05-27 CA CA2765233A patent/CA2765233A1/en not_active Abandoned
- 2010-05-27 MX MX2011013113A patent/MX2011013113A/es not_active Application Discontinuation
- 2010-05-27 EA EA201270011A patent/EA201270011A1/ru unknown
- 2010-05-27 AU AU2010259102A patent/AU2010259102B2/en not_active Ceased
- 2010-05-27 BR BRPI1012931A patent/BRPI1012931A2/pt not_active IP Right Cessation
- 2010-05-27 UA UAA201200346A patent/UA104762C2/ru unknown
- 2010-05-27 WO PCT/US2010/036365 patent/WO2010144265A2/en active Application Filing
- 2010-06-04 TW TW099118111A patent/TW201106961A/zh unknown
- 2010-06-08 US US12/796,001 patent/US20100317581A1/en not_active Abandoned
-
2011
- 2011-11-23 CR CR20110618A patent/CR20110618A/es unknown
- 2011-12-07 NI NI201100212A patent/NI201100212A/es unknown
- 2011-12-09 DO DO2011000383A patent/DOP2011000383A/es unknown
- 2011-12-12 CU CU20110232A patent/CU20110232A7/es unknown
- 2011-12-12 GT GT201100318A patent/GT201100318A/es unknown
- 2011-12-12 EC ECSP11011516 patent/ECSP11011516A/es unknown
- 2011-12-12 CL CL2011003131A patent/CL2011003131A1/es unknown
- 2011-12-12 CO CO11170483A patent/CO6470880A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CR20110618A (es) | 2012-03-02 |
| CL2011003131A1 (es) | 2012-08-17 |
| JP2012529510A (ja) | 2012-11-22 |
| DOP2011000383A (es) | 2012-05-31 |
| WO2010144265A3 (en) | 2011-11-24 |
| CU20110232A7 (es) | 2012-06-21 |
| CO6470880A2 (es) | 2012-06-29 |
| CA2765233A1 (en) | 2010-12-16 |
| US20100317581A1 (en) | 2010-12-16 |
| EP2440180B1 (en) | 2014-08-27 |
| SG176717A1 (en) | 2012-01-30 |
| MX2011013113A (es) | 2012-02-21 |
| UA104762C2 (ru) | 2014-03-11 |
| NZ596641A (en) | 2013-12-20 |
| EA201270011A1 (ru) | 2012-05-30 |
| WO2010144265A2 (en) | 2010-12-16 |
| KR20120030530A (ko) | 2012-03-28 |
| BRPI1012931A2 (pt) | 2018-01-30 |
| AU2010259102A1 (en) | 2012-01-12 |
| TW201106961A (en) | 2011-03-01 |
| ECSP11011516A (es) | 2012-03-30 |
| AU2010259102B2 (en) | 2013-09-12 |
| EP2440180A2 (en) | 2012-04-18 |
| CN102481251A (zh) | 2012-05-30 |
| GT201100318A (es) | 2014-10-13 |
| PE20121064A1 (es) | 2012-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119269T1 (el) | Θεραπεια βλαβων που προκαλουνται απο ιους | |
| PE20130396A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma | |
| UA105229C2 (uk) | Фармацевтичний склад | |
| PE20130511A1 (es) | Formulaciones de insulina de accion prolongada | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| ATE415185T1 (de) | Kosmetische formulierung auf mikroemulsionsbasis enthaltend mandelsäure | |
| BR112014017169A2 (pt) | máquina de bebidas com módulo removível | |
| UY32731A (es) | Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| AR059097A1 (es) | Tratamiento a largo plazo de la infeccion por vih | |
| WO2008047061A3 (fr) | Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine eventuellement associee a au moins un compose polyphenol et composition correspondante | |
| AR084187A1 (es) | Composiciones para el cuidado oral | |
| NI201100212A (es) | Inyección de diacetato de ipamorelin y soluciones de la infusión | |
| CO6310996A2 (es) | Composicion fungicida que contiene un compuesto de imidazol en combinación con polioxinas | |
| UY32894A (es) | Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica | |
| AR026960A1 (es) | Formulaciones liquidas insecticidas, aplicables de forma dermica, para la lucha contra las larvas parasitantes de insectos | |
| ECSP088893A (es) | 2-alcoxi-3, 4,5-trihidroxi-alquilamida-benzazepinas, su preparación, composiciones que las contienen y utilización | |
| UA105034C2 (uk) | Фармацевтична комбінація 5-фторурацилу і похідного 1,4-дигідропіридину та її застосування в лікуванні раку | |
| TR200802061A2 (tr) | Yüksek oranda aktif madde içeren farmasötlk formülasyon. | |
| JP2011093891A5 (es) | ||
| TR200806302A2 (tr) | Çözünürlük ve stabilite artırıcı farmasötik formülasyon. | |
| MX2010007632A (es) | Composicion farmaceutica estable. | |
| UA110329C2 (en) | Conjugates of fatty acids and niacin and their use | |
| SMT201400121B (it) | Composizione in combinazione, compredente come ingrediente attivo l-carnitina o propionil l-carnitina, per la prevenzione o il trattamento dell'insufficienza venosa cronica | |
| TR200806301A2 (tr) | Çözünürlük ve stabilite artırıcı farmasötik formülasyon. |